Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2022

View Archived Issues

Study shows disease-linked DNA variants are active at different stages of T-cell activation

Pendrin inhibitor ARBM-201 reduces lung injury in acute respiratory distress syndrome model

NLRP3 inflammasome inhibitor INF-176 for the treatment of Alzheimer's disease

MAb-loaded extracellular vesicles show potential as cancer therapeutics

Shanghai Yao Biotech discloses new TRK inhibitors

Sichuan Haisco Pharmaceutical patents ENPP2 inhibitors

Tyligand Bioscience divulges GTPase KRAS mutant inhibitors

Betta Pharmaceuticals identifies new IDH inhibitors

Broadenbio synthesizes new MAP4K1 inhibitors

Morc2 S87L mutation in mice mimics human Charcot-Marie-Tooth disease

TrxR inhibitor Au-24 shows promise in vivo and in vitro for treating hepatocellular carcinoma

Atux Iskay presents preclinical data on PP2A activator ATUX-792 in IPF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...